Compare ProShares Ultra Silver ETF (AGQ) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Citius Pharmaceuticals Inc — how do they compare? ProShares Ultra Silver ETF trades at $81.13, while Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M). Which is the better fit depends on your goals.
| AGQ | CTXR | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $1.82 |
52-Week Low | $49.73 | $0.48 |
Market Cap | — | $20.01M |
Enterprise Value | — | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGQ, the ProShares Ultra Silver ETF, trades at $83.06, up 1.44% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights its volatility, surging 9.39% on silver rallies but facing structural decay concerns due to 2x daily leverage. Financial ratios are unavailable as it is an ETF tracking silver futures.
Outlook is highly speculative, offering amplified silver exposure with significant risk. Opportunities exist if silver prices rise, but risks include leverage decay, volatility-driven losses, and silver market downturns. Investors should weigh aggressive gains against potential rapid declines.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
